Ondine Biomedical Launches Phase 3 Trial of Nasal Photodisinfection for Surgical Infection Prevention
• Ondine Biomedical has initiated a Phase 3 clinical trial, LANTERN, to evaluate its non-antibiotic nasal photodisinfection technology in preventing surgical site infections.
• The trial will enroll approximately 5,000 patients across 14 hospitals, comparing standard infection prevention practices with and without Ondine's technology.
• Ondine's nasal photodisinfection is a 5-minute procedure that uses a photosensitive agent and red light to eliminate pathogens, addressing antimicrobial resistance concerns.
• Preliminary results from the LANTERN trial, conducted in collaboration with HCA Healthcare, are expected in Autumn 2025.
King's College Hospital to Pilot Ondine Biomedical's Steriwave for HAI Prevention
• King's College Hospital will pilot Ondine Biomedical's Steriwave technology as part of a quality improvement initiative to prevent hospital-acquired infections (HAIs).
• Steriwave uses a light-activated agent to eliminate infection-causing pathogens in a rapid, five-minute treatment, offering an alternative to antibiotics.
• Mid Yorkshire Teaching NHS Trust adopted Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients in March 2024.
• Steriwave's accessibility has increased across England and Wales after its addition to the NHS Supply Chain in June 2024, facilitating broader adoption.
Ondine Biomedical's Steriwave Receives Regulatory Approval in the UAE
• Ondine Biomedical has secured regulatory approval in the United Arab Emirates (UAE) for its Steriwave nasal decolonization system, designed to reduce healthcare-associated infections (HAIs).
• Steriwave employs a light-activated antimicrobial technology to eliminate pathogens in the nasal passages, offering a rapid, five-minute treatment that minimizes the risk of antimicrobial resistance.
• The UAE represents a growing market in the Middle East for medical tourism, with wellness tourists spending an estimated $5.4 billion, marking a significant increase from $2.1 billion in 2020.
• Nasal decolonization is recommended by global guidelines for surgical site infection prevention, positioning Steriwave as a valuable addition to presurgical and ICU protocols in the region.
© Copyright 2025. All Rights Reserved by MedPath